CY1120831T1 - Μεθοδοι μειωσης της συσσωματωσης toy il-1ra - Google Patents

Μεθοδοι μειωσης της συσσωματωσης toy il-1ra

Info

Publication number
CY1120831T1
CY1120831T1 CY181101118T CY181101118T CY1120831T1 CY 1120831 T1 CY1120831 T1 CY 1120831T1 CY 181101118 T CY181101118 T CY 181101118T CY 181101118 T CY181101118 T CY 181101118T CY 1120831 T1 CY1120831 T1 CY 1120831T1
Authority
CY
Cyprus
Prior art keywords
methods
accumulation
reducing
reducing toy
toy
Prior art date
Application number
CY181101118T
Other languages
English (en)
Inventor
Andrei Raibekas
Bruce Kerwin
Original Assignee
Swedish Orphan Biovitrum Ab Publ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Swedish Orphan Biovitrum Ab Publ filed Critical Swedish Orphan Biovitrum Ab Publ
Publication of CY1120831T1 publication Critical patent/CY1120831T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Παρέχονται μέθοδοι μείωσης της συσσωμάτωσης ενός συσσωματούμενου IL-1ra που περιλαμβάνουν επώαση του IL-1ra με τουλάχιστον ένα βοηθητικό μόριο. Παρέχονται επίσης κιτ που περιέχουν IL-1ra και τουλάχιστον ένα βοηθητικό μόριο. Παρέχονται επίσης φαρμακευτικές συνθέσεις που περιέχουν IL-1ra και τουλάχιστον ένα βοηθητικό μόριο.
CY181101118T 2004-04-02 2018-10-30 Μεθοδοι μειωσης της συσσωματωσης toy il-1ra CY1120831T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US55916104P 2004-04-02 2004-04-02
US55887904P 2004-04-02 2004-04-02
US60122904P 2004-08-12 2004-08-12
US60121604P 2004-08-12 2004-08-12
PCT/US2005/011332 WO2005097195A2 (en) 2004-04-02 2005-04-01 Methods of reducing aggregation of il-1ra

Publications (1)

Publication Number Publication Date
CY1120831T1 true CY1120831T1 (el) 2019-12-11

Family

ID=34964860

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181101118T CY1120831T1 (el) 2004-04-02 2018-10-30 Μεθοδοι μειωσης της συσσωματωσης toy il-1ra

Country Status (17)

Country Link
US (3) US7619066B2 (el)
EP (1) EP1729810B1 (el)
JP (3) JP2007531738A (el)
AU (1) AU2005231822B2 (el)
CA (1) CA2557910C (el)
CY (1) CY1120831T1 (el)
DK (1) DK1729810T3 (el)
ES (1) ES2694252T3 (el)
HR (1) HRP20181848T1 (el)
HU (1) HUE040595T2 (el)
LT (1) LT1729810T (el)
PL (1) PL1729810T3 (el)
PT (1) PT1729810T (el)
RS (1) RS57852B1 (el)
SI (1) SI1729810T1 (el)
TR (1) TR201816556T4 (el)
WO (1) WO2005097195A2 (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005227258A1 (en) * 2004-03-09 2005-10-06 Merck & Co., Inc. HIV integrase inhibitors
PT1729810T (pt) * 2004-04-02 2018-11-22 Swedish Orphan Biovitrum Ab Publ Métodos de redução da agregação de il-ira
US10105441B2 (en) * 2007-08-16 2018-10-23 The Schepens Eye Research Institute, Inc. Method for inhibiting or reducing dry eye disease by IL-1Ra
CN101690801B (zh) * 2009-10-26 2012-08-01 上海交通大学 白细胞介素-1受体拮抗剂的用途及其药物组合物
EP2598526B1 (en) 2010-07-29 2018-09-05 Eleven Biotherapeutics, Inc. Chimeric il-1 receptor type i agonists and antagonists
US9198954B2 (en) * 2011-02-11 2015-12-01 Swedish Orphan Biovitrum Ab (Publ) Citrate free pharmaceutical compositions comprising anakinra
CN103476933B (zh) 2011-03-14 2016-04-13 弗洛格有限公司 白介素1受体的拮抗剂
RU2014107743A (ru) * 2011-07-29 2015-09-10 Илэвэн Байотерапьютикс, Инк. Очищенные белки
ES2842677T3 (es) 2012-06-08 2021-07-14 Alkermes Pharma Ireland Ltd Ligandos modificados mediante permutación circular como agonistas y antagonistas
SG11201507447PA (en) * 2013-03-13 2015-10-29 Eleven Biotherapeutics Inc Chimeric cytokine formulations for ocular delivery
EP3003369A4 (en) * 2013-05-28 2017-04-26 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions comprising pyrophosphate
CA2983783A1 (en) * 2015-04-28 2016-11-03 Swedish Orphan Biovitrum Ab (Publ) Compositions comprising anakinra
AU2017371043B2 (en) * 2016-12-07 2022-12-15 University Of Florida Research Foundation, Incorporated IL-1Ra cDNAs

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4226846A (en) * 1977-04-01 1980-10-07 New England Nuclear Corporation Albumin microaggregates for radioactive scanning of reticuloendothelial systems
EP0569687B1 (en) * 1984-05-18 2002-08-21 New England Medical Center Hospitals, Inc. Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
US5359032A (en) * 1987-08-26 1994-10-25 Biogen Inc. Interkeukin-1 inhibitor
US5081228A (en) * 1988-02-25 1992-01-14 Immunex Corporation Interleukin-1 receptors
WO1989004838A1 (en) * 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US5296592A (en) * 1987-11-25 1994-03-22 Immunex Corporation Process for purifying interleukin-1 receptors
US4968607A (en) * 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US6511665B1 (en) * 1987-11-25 2003-01-28 Immunex Corporation Antibodies to interleukin-1 receptors
US5319071A (en) * 1987-11-25 1994-06-07 Immunex Corporation Soluble interleukin-1 receptors
US5075222A (en) * 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
CA2010321C (en) * 1989-02-21 2004-04-06 Thomas F. Tedder Lymphocyte-associated cell surface protein
EP0502956B1 (en) 1989-11-29 1997-04-23 Amgen Boulder Inc. Production of recombinant human interleukin-1 inhibitor
WO1992011359A1 (en) 1990-12-20 1992-07-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education A truncated interleukin-1 receptor gene for the treatment of arthritis
US5591457A (en) * 1992-02-07 1997-01-07 Vasogen Inc Method of inhibiting the aggregation of blood platelets and stimulating the immune systems of a human
US5980954A (en) * 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
CZ291261B6 (cs) * 1992-09-17 2003-01-15 Amgen Inc. Farmaceutická kompozice pro léčení nemocí zprostředkovaných interleukinem-1
US6242417B1 (en) * 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
US5756466A (en) * 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
PE64396A1 (es) 1995-01-23 1997-01-28 Hoffmann La Roche Proteina accesoria del receptor de la interleucina 1
EP0904112B1 (en) * 1996-02-09 2009-11-18 Amgen Inc., Composition comprising il-1ra as interleukin-1 inhibitor and hyaluronan as controlled release polymer
US6096728A (en) * 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6416753B1 (en) * 1996-03-15 2002-07-09 The General Hospital Corporation Method for modulating apoptosis
AU7011696A (en) 1996-08-26 1998-03-19 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
US5780431A (en) 1996-09-20 1998-07-14 Neurobiological Technologies, Inc. Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
US6054559A (en) 1997-01-28 2000-04-25 Smithkline Beecham Corporation Interleukin-1 receptor antagonist beta (IL-1raβ)
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US6541623B1 (en) 1998-04-03 2003-04-01 Hyseq, Inc. Interleukin—1 receptor antagonist and uses thereof
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
AU2915801A (en) 1999-09-07 2001-05-10 Colorado State University Research Foundation In vivo treatment of joint disease using interleukin-1 receptor antagonists
BR0014003A (pt) 1999-09-14 2002-05-21 Pfizer Prod Inc Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra
US6323311B1 (en) * 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
US6525102B1 (en) * 1999-10-04 2003-02-25 Chiron Corporation Stabilized liquid polypeptide-containing pharmaceutical compositions
US7087224B2 (en) 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
JP2004519230A (ja) 2001-02-06 2004-07-02 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 低減された免疫原性を有する修飾されたインターロイキン−１受容体アンタゴニスト（ｉｌ−１ｒａ）
US7572770B2 (en) * 2002-06-27 2009-08-11 University Of Zurich Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes
ES2565189T3 (es) 2002-09-06 2016-04-01 Amgen, Inc Anticuerpo monoclonal anti-IL-1R1 humano terapéutico
DK2236154T3 (en) * 2003-02-10 2018-06-25 Biogen Ma Inc IMMUNOGLOBULIN INFORMATION AND METHOD OF PREPARING IT
US20050159590A1 (en) * 2003-08-25 2005-07-21 Galit Rotman Variants of interleukin-1 receptor antagonist: compositions and uses thereof
PT1729810T (pt) * 2004-04-02 2018-11-22 Swedish Orphan Biovitrum Ab Publ Métodos de redução da agregação de il-ira

Also Published As

Publication number Publication date
HRP20181848T1 (hr) 2018-12-28
WO2005097195A2 (en) 2005-10-20
EP1729810B1 (en) 2018-08-15
ES2694252T3 (es) 2018-12-19
US20210121571A1 (en) 2021-04-29
CA2557910C (en) 2012-05-29
EP1729810A2 (en) 2006-12-13
US10765747B2 (en) 2020-09-08
WO2005097195A3 (en) 2006-08-03
AU2005231822A1 (en) 2005-10-20
JP6181375B2 (ja) 2017-08-16
JP6041843B2 (ja) 2016-12-14
JP2015078195A (ja) 2015-04-23
AU2005231822B2 (en) 2011-07-21
US20050271618A1 (en) 2005-12-08
RS57852B1 (sr) 2018-12-31
SI1729810T1 (sl) 2018-12-31
PL1729810T3 (pl) 2019-02-28
PT1729810T (pt) 2018-11-22
JP2007531738A (ja) 2007-11-08
CA2557910A1 (en) 2005-10-20
LT1729810T (lt) 2018-11-26
US20070098684A9 (en) 2007-05-03
HUE040595T2 (hu) 2019-03-28
US7619066B2 (en) 2009-11-17
US20050282752A1 (en) 2005-12-22
TR201816556T4 (tr) 2018-11-21
JP2013136588A (ja) 2013-07-11
DK1729810T3 (en) 2018-12-03

Similar Documents

Publication Publication Date Title
CY1120831T1 (el) Μεθοδοι μειωσης της συσσωματωσης toy il-1ra
CY1118760T1 (el) Τροποποιημενα αντισωματα εναντι il-23
CY1116373T1 (el) Φαρμακευτικα σκευασματα που περιεχουν μεθυλναλτρεξονη
BRPI0414000B8 (pt) composição farmacêutica sólida oral de liberação prolongada contendo tacrolimus na forma de uma dispersão sólida, forma de dosagem, e, uso da composição farmacêutica
CY1119742T1 (el) Βιολογικα συστηματα μεταφορας πολλαπλου-συστατικου
CY1109010T1 (el) γ-ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ ΙΒΑΒΡΑΔΙΝΗΣ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΤΗΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΕΧΟΥΝ
DE602006015793D1 (de) Proteolipidmembran und lipidmembranen-biosensor
CY1110337T1 (el) Παρασκευη πρεγκαμπαλινης και σχετικων ενωσεων
ATE537263T1 (de) Kationische lipide und verwendungsverfahren
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
CY1113199T1 (el) Σταθεροποιημενες συνθεσεις γλυκοσερεμπροσιδασης
CY1110780T1 (el) Τοπικα σκευασματα νεπαφενακης
ATE495730T1 (de) Alkaloid-formulierungen
WO2006108075A3 (en) Compositions and methods for enhancing drug sensitivity and treating drug resistant infections an diseases
NO20083127L (no) Fremgangsmater og preparater for malretting av polyubiquitin
CY1107773T1 (el) Τυποποιησεις που περιεχουν εκτεïνασκιδινη και δισακχαριτη
ECSP088203A (es) Dispersiones amorfas sólidas
WO2006052409A3 (en) Peptide and small molecule agonists of epha and their uses
CY1120206T1 (el) Μεθοδοι για τη συγκλινουσα συνθεση παραγωγων καλιχεαμικινης
PA8667201A1 (es) Nuevos compuestos farmaceuticos
DE60326859D1 (de) Arzneimittelverabreichung
ECSP066822A (es) Macrólidos y métodos para producir los mismos
CY1112591T1 (el) Απο του στοματος φαρμακοτεχνικες μορφες της κλαντριβινης
WO2006097617A3 (fr) Nouveaux derives dihydropyrimidines et leur utilisation comme agents anti-cancereux
CY1110213T1 (el) Παραγωγα αζολοπυριδιν-2-ονης ως αναστολεις λιπασων και φωσφολιπασων